Infos zu Corona - Aktuelle Informationen zu SARS-CoV-2 : 12 Risikogruppen?/ risk groups

12 Risikogruppen?/ risk groups » Immunsuppression/Immundefizienz

Letzte Änderung: 05.08.2023 um 15:26 Uhr

Immunsupprimierte Patienten haben nicht alle das gleiche Erkrankungsrisiko. Es gibt schwächere Immunsuppression oder stärkere. Teils sind nur die BZellen reduziert, teils daneben auch gleichzeitig zu wenig TZellen vorhanden. Insbesondere wenn weder humorale noch zelluläre Immunantworten gebildet werden können, besteht das grösste Risiko auf einen schweren Akutverlauf, persistierende Infektionen und auch Long Covid.

Personen die nach Coronaimpfungen keine eigenen Antikörper bilden können haben jedenfalls ein erhöhtes Risiko schwerer Erkrankung; hinzukommen können weitere Risikofaktoren wie andere Vorerkrankungen, Medikationen, zusätzliche Formen der Immunsuppression (TZelldepletion) usw.. Ärzte müssen Informationen über aller Vorerkrankungen und die Blutwerte haben, um Risiken realistisch abschätzen zu können. Auch haftungsrechtlich ist eine im Zweifel vorsichtigere Behandlung des Patienten angezeigt.

Neben einen erhöhten Risiko eines schweren akuten Krankheitsverlaufs besteht bei stark immunsupprimierten Patienten auch ein erhöhtes Risiko einer persistierenden Infektion, bei der der Patient lange Zeit coronapositiv bleibt, mit nicht selten tödlichem Ausgang nach teils monatelanger Erkrankung. Auch bei nicht starker Immunsuppression könnte es mehr Langzeitfolgen geben.

Weiterführende Links zum Artikel

★ SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency (Hinzugefügt: 05.08.2023 um 12:09 Uhr)
https://www.medrxiv.org/content/10.1101/2023.07.31.23293441v1
★ Rezidivierende SARS-CoV-2-Infektionen bei Immundefizienz (Hinzugefügt: 30.10.2022 um 09:19 Uhr)
https://link.springer.com/article/10.1007/s00108-022-01424-7
★ Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses (Hinzugefügt: 24.06.2022 um 09:43 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00226-4
★ Anspruch auf COVID-Antikörperprophylaxe neu geregelt (Hinzugefügt: 05.06.2022 um 15:35 Uhr)
https://www.aerzteblatt.de/nachrichten/134744/Anspruch-auf-COVID-Antikoerperprophylaxe-neu-geregelt
★ SARS-CoV-2 evolution and immune escape in immunocompromised patients treated with exogenous antibodies (Hinzugefügt: 26.04.2022 um 13:42 Uhr)
https://www.medrxiv.org/content/10.1101/2022.04.12.22273675v1
★ Préconisations pour protéger les patients de la filière oncologique face au variant OmicronRecommendations to protect patients with cancer against the Omicron variant (Hinzugefügt: 22.01.2022 um 13:29 Uhr)
https://www.sciencedirect.com/science/article/pii/S0007455121006858
★ Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants (Hinzugefügt: 06.05.2021 um 09:15 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2779850?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=050521#.YJM4kz9cbTc.twitter
★ SARS-CoV-2 evolution during treatment of chronic infection (Hinzugefügt: 05.02.2021 um 20:21 Uhr)
https://www.nature.com/articles/s41586-021-03291-y
Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19 (Hinzugefügt: 05.08.2023 um 15:26 Uhr)
https://www.sciencedirect.com/science/article/pii/S2213219822010431
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments (Hinzugefügt: 10.04.2023 um 14:29 Uhr)
https://www.jci.org/articles/view/166032
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern (Hinzugefügt: 10.04.2023 um 14:29 Uhr)
https://www.jci.org/articles/view/168603
Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients (Hinzugefügt: 10.04.2023 um 13:56 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad181/7091553
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity (Hinzugefügt: 07.04.2023 um 17:48 Uhr)
https://www.nature.com/articles/s41467-023-36686-8
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19 (Hinzugefügt: 07.04.2023 um 17:41 Uhr)
https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6035
COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada (Hinzugefügt: 07.04.2023 um 17:31 Uhr)
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00035-2/fulltext?fbclid=IwAR17kpFAD6PPOD-1OEsFefM2Xs8TWwmPB2g4R6PH6XK0vvqbtwdaSLI7RC4
SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual (Hinzugefügt: 06.12.2022 um 17:00 Uhr)
https://www.medrxiv.org/content/10.1101/2022.11.23.22282673v2
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review (Hinzugefügt: 25.11.2022 um 15:52 Uhr)
https://www.sciencedirect.com/science/article/pii/S2590170222000784
SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual (Hinzugefügt: 25.11.2022 um 15:52 Uhr)
https://www.medrxiv.org/content/10.1101/2022.11.23.22282673v1
SARS-CoV-2 in immunocompromised individuals (Hinzugefügt: 19.11.2022 um 20:19 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(22)00500-3#relatedArticles
Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients (Hinzugefügt: 19.11.2022 um 18:23 Uhr)
https://onlinelibrary.wiley.com/doi/full/10.1111/tid.13967?campaign=wolearlyview
Patient cured of Covid after fighting virus for more than 400 days (Hinzugefügt: 14.11.2022 um 13:16 Uhr)
https://www.manchestereveningnews.co.uk/news/uk-news/patient-cured-covid-after-fighting-25430450
«Prolongierter Virusnachweis bei SARS-CoV-2-Infektion unter Immunsuppression» (Hinzugefügt: 10.11.2022 um 16:00 Uhr)
https://medicalforum.ch/de/detail/doi/smf.2022.09020
This Man Had COVID For Over 400 Days. Scientists Explain Why (Hinzugefügt: 10.11.2022 um 15:59 Uhr)
https://www.sciencealert.com/this-man-had-covid-for-over-400-days-scientists-explain-why
Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study (Hinzugefügt: 17.08.2022 um 10:27 Uhr)
https://www.medrxiv.org/content/10.1101/2022.08.08.22278576v1
Intra-host evolution during SARS-CoV-2 prolonged infection (Hinzugefügt: 24.06.2022 um 09:40 Uhr)
https://academic.oup.com/ve/article/7/2/veab078/6377925
How months-long COVID infections could seed dangerous new variants (Hinzugefügt: 24.06.2022 um 08:05 Uhr)
https://www.nature.com/articles/d41586-022-01613-2
Opinion: To Prevent Future Variants, We Must Protect Those Most At Risk (Hinzugefügt: 24.06.2022 um 08:04 Uhr)
https://undark.org/2022/03/17/to-prevent-future-variants-we-must-protect-immunocompromised/
More than a ‘Hundred Days War’: Persistent SARS-CoV-2 infection in a patient with ANCA-associated vasculitis (Hinzugefügt: 24.06.2022 um 08:03 Uhr)
https://jammi.utpjournals.press/doi/full/10.3138/jammi-2021-0033
The association between pre-exposure to glucocorticoids and other immunosuppressant drugs with severe COVID-19 outcomes (Hinzugefügt: 08.06.2022 um 10:21 Uhr)
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00270-1/fulltext?dgcid=raven_jbs_aip_email
Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant (Hinzugefügt: 06.06.2022 um 09:07 Uhr)
https://www.medrxiv.org/content/10.1101/2022.05.25.22275533v1
The COVID-19 Pandemic Rages on for People Who Are Immunocompromised (Hinzugefügt: 13.05.2022 um 07:39 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2791868
Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host (Hinzugefügt: 13.05.2022 um 07:09 Uhr)
https://www.nature.com/articles/s41467-022-30163-4
Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022 (Hinzugefügt: 09.05.2022 um 09:00 Uhr)
https://wwwnc.cdc.gov/eid/article/28/7/22-0467_article
The COVID-19 Pandemic Rages on for People Who Are Immunocompromised (Hinzugefügt: 30.04.2022 um 11:13 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2791868?resultClick=1
Severe COVID-19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals (Hinzugefügt: 26.04.2022 um 13:28 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/cti2.1365
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet) (Hinzugefügt: 26.04.2022 um 13:04 Uhr)
https://link.springer.com/article/10.1007/s10875-022-01264-y
UK patient had COVID for 505 days (Hinzugefügt: 26.04.2022 um 12:30 Uhr)
https://www.kcl.ac.uk/news/uk-patient-had-covid-for-505-days
Patient über 16 Monate mit SARS-CoV-2 infiziert – auch okkulte Infektion möglich (Hinzugefügt: 26.04.2022 um 12:28 Uhr)
https://www.aerzteblatt.de/nachrichten/133576/Patient-ueber-16-Monate-mit-SARS-CoV-2-infiziert-auch-okkulte-Infektion-moeglich
Longitudinal evolution of SARS-CoV-2 in immunocompromised individuals with persistent infection (Hinzugefügt: 26.04.2022 um 12:27 Uhr)
https://drive.google.com/file/d/11XHMYIhk-EOxfo_z5AhpFIjY0ieP5Aky/view
Longest known COVID-19 infection – 505 days – described by UK researchers (Hinzugefügt: 26.04.2022 um 12:17 Uhr)
https://www.escmid.org/fileadmin/src/media/PDFs/2News_Discussions/Press_activities/2022/2022-04-21_Longest_known_COVID-19_infection_.pdf
Some cases of long COVID-19 may be caused by an abnormally suppressed immune system (Hinzugefügt: 26.04.2022 um 11:49 Uhr)
https://medicalxpress.com/news/2022-04-cases-covid-abnormally-suppressed-immune.html
COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge (Hinzugefügt: 13.04.2022 um 15:29 Uhr)
https://journals.lww.com/transplantjournal/fulltext/9900/covid_19_clinical_outcomes_in_solid_organ.18.aspx
Prolonged SARS-CoV-2 shedding in a person living with advanced HIV and diffuse large B-cell lymphoma: a case report (Hinzugefügt: 03.04.2022 um 18:00 Uhr)
https://www.tandfonline.com/doi/full/10.1080/23744235.2022.2055136
Acute exacerbation of graft-versus-host disease following SARS-CoV2 infection after hematopoietic stem cell transplant in two pediatric patients (Hinzugefügt: 18.03.2022 um 09:35 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/pbc.29661
Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations (Hinzugefügt: 18.03.2022 um 09:34 Uhr)
https://www.thelancet.com/action/showPdf?pii=S2666-5247%2822%2900061-1
SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity (Hinzugefügt: 17.03.2022 um 11:07 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2022.840126/full
Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients (Hinzugefügt: 11.03.2022 um 11:16 Uhr)
https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(22)00028-6
The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient (Hinzugefügt: 11.03.2022 um 11:13 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.04.22271540v1
The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient. (Hinzugefügt: 08.03.2022 um 10:41 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.04.22271540v1
Recurrent SARS-CoV-2 Mutations in Immunodeficient Patients (Hinzugefügt: 06.03.2022 um 18:32 Uhr)
https://www.medrxiv.org/content/10.1101/2022.03.02.22271697v1
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection (Hinzugefügt: 06.03.2022 um 18:30 Uhr)
https://www.nature.com/articles/s41375-021-01175-8
Whole-Genome Sequencing of SARS-CoV-2 Infection in a Cluster of Immunocompromised Children in Indonesia (Hinzugefügt: 06.03.2022 um 18:25 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2022.835998/full
Vaccinated but Not Protected—Living Immunocompromised During the Pandemic (Hinzugefügt: 19.02.2022 um 13:26 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2781012
Immunocompromised Americans’ Terrifying Reality During COVID (Hinzugefügt: 17.02.2022 um 07:35 Uhr)
https://www.pbs.org/wnet/amanpour-and-company/video/immunocompromised-americans-terrifying-reality-during-covid/
Persistent SARS-CoV-2 Infection with Accumulation of Mutations in a Patient with Poorly Controlled HIV Infection (Hinzugefügt: 17.02.2022 um 07:04 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4014499
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the United Kingdom (Hinzugefügt: 17.02.2022 um 06:10 Uhr)
https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxac008/6515671
Individuals with immunodeficiency at high risk of mortality following SARS-CoV-2 infection (Hinzugefügt: 17.02.2022 um 05:53 Uhr)
https://www.immunology.org/news/individuals-immunodeficiency-high-risk-mortality-following-sars-cov-2-infection
Another Variant Emerges From An Immunocompromised Patient (Hinzugefügt: 24.01.2022 um 20:11 Uhr)
https://www.forbes.com/sites/williamhaseltine/2021/12/21/another-variant-emerges-from-an-immunocompromised-patient/?sh=4fb674b6671c
https://www.dailymail.co.uk/health/article-10406071/What-happens-500-000-people-shielding.html (Hinzugefügt: 22.01.2022 um 13:17 Uhr)
https://www.dailymail.co.uk/health/article-10406071/What-happens-500-000-people-shielding.html
Antibody and antiviral treatments for people with blood cancer (Hinzugefügt: 23.12.2021 um 20:13 Uhr)
https://bloodcancer.org.uk/support-for-you/coronavirus-covid-19/covid-vaccine-blood-cancer/covid-antibody-treatment/
Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases. (Hinzugefügt: 19.11.2021 um 16:44 Uhr)
https://www.jrheum.org/content/early/2021/03/10/jrheum.200755
Kasus: Patientin war über 11 Monate mit SARS-CoV-2 infiziert (Hinzugefügt: 19.11.2021 um 16:03 Uhr)
https://www.aerzteblatt.de/nachrichten/128340/Kasus-Patientin-war-ueber-11-Monate-mit-SARS-CoV-2-infiziert
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative (Hinzugefügt: 19.11.2021 um 15:26 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00325-8/fulltext
Outcomes for hospitalized COVID-19 patients taking immunosuppressive medications similar to non-immunosuppressed patients (Hinzugefügt: 19.11.2021 um 15:25 Uhr)
https://www.eurekalert.org/news-releases/935179
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants (Hinzugefügt: 15.11.2021 um 07:36 Uhr)
https://www.nature.com/articles/s41467-021-26602-3
Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report (Hinzugefügt: 01.11.2021 um 09:54 Uhr)
https://link.springer.com/article/10.1007/s10875-021-01158-5
Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient (Hinzugefügt: 01.11.2021 um 09:47 Uhr)
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab553/6414393
Clinical characteristics of COVID-19 patients with HIV coinfection in Wuhan, China (Hinzugefügt: 29.10.2021 um 11:49 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605649/
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (Hinzugefügt: 29.10.2021 um 11:39 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00278-7/fulltext
Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion (Hinzugefügt: 23.10.2021 um 07:19 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.02.21264267v2
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice (Hinzugefügt: 05.10.2021 um 08:18 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00224-1/fulltext
Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies (Hinzugefügt: 15.09.2021 um 15:34 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.25.21262417v1
SARS-CoV-2 Variants in Patients with Immunosuppression (Hinzugefügt: 26.08.2021 um 04:11 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMsb2104756
COVID-19 Infection, Admission and Death Amongst People with Rare Autoimmune Rheumatic Disease in England. Results from the RECORDER Project (Hinzugefügt: 24.08.2021 um 16:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.17.21260846v2
SARS-CoV-2 Variants in Patients with Immunosuppression (Hinzugefügt: 06.08.2021 um 11:21 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMsb2104756
COVID-19: Serumtherapie kann bei hämatologischen Krebspatienten erfolgreich sein (Hinzugefügt: 23.06.2021 um 18:01 Uhr)
https://www.aerzteblatt.de/nachrichten/124857/COVID-19-Serumtherapie-kann-bei-haematologischen-Krebspatienten-erfolgreich-sein
SARS-CoV-2 shedding, infectivity and evolution in an immunocompromised adult patient (Hinzugefügt: 20.06.2021 um 17:53 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.11.21257717v1
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ (Hinzugefügt: 27.05.2021 um 12:04 Uhr)
https://ard.bmj.com/content/early/2021/05/12/annrheumdis-2021-220588
Metaanalyse: COVID-19 bei HIV-Infizierten häufiger tödlich (Hinzugefügt: 15.05.2021 um 10:02 Uhr)
https://www.aerzteblatt.de/nachrichten/123833/Metaanalyse-COVID-19-bei-HIV-Infizierten-haeufiger-toedlich
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient: a source of immune escape variants (Hinzugefügt: 06.05.2021 um 09:28 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.30.21256244v1
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study (Hinzugefügt: 30.04.2021 um 05:56 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00112-0/fulltext
Relief and worry for immune-suppressed people (Hinzugefügt: 30.04.2021 um 05:44 Uhr)
https://science.sciencemag.org/content/372/6541/443.full
Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment (Hinzugefügt: 12.04.2021 um 18:09 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.08.21254791v1
Innate immune deficiencies in patients with COVID-19 (Hinzugefügt: 01.04.2021 um 05:47 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.29.21254560v1
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study (Hinzugefügt: 27.03.2021 um 04:05 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00059-X/fulltext
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients (Hinzugefügt: 26.03.2021 um 08:00 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777685
Risk of severe coronavirus infection (COVID-19) in patients with inflammatory rheumatic diseases (Hinzugefügt: 17.03.2021 um 02:52 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33722949/
Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy (Hinzugefügt: 17.03.2021 um 02:51 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910130/
Corona-Mutationen Das Virus nutzt die Schwachen aus (Hinzugefügt: 17.03.2021 um 02:08 Uhr)
https://www.spiegel.de/wissenschaft/mensch/corona-menschen-mit-geschwaechtem-immunsystem-sind-offenbar-perfekte-wirte-fuer-das-coronavirus-a-78d1c66f-2b32-4373-b64e-a31cc92a6159
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms (Hinzugefügt: 17.03.2021 um 01:45 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00355-X
Protracted SARS-CoV-2 Pneumonia with Rituximab Treatment: about two cases (Hinzugefügt: 13.03.2021 um 22:02 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26921
Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity (Hinzugefügt: 03.03.2021 um 08:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.27.21252099v1
Rheumatologen aktualisieren Empfehlungen zu Therapie und COVID-19-Impfung (Hinzugefügt: 03.03.2021 um 07:55 Uhr)
https://www.aerzteblatt.de/nachrichten/121656/Rheumatologen-aktualisieren-Empfehlungen-zu-Therapie-und-COVID-19-Impfung
Rezeptormangel auf Immunzellen könnte mit schwerem COVID-19-Verlauf verbunden sein (Hinzugefügt: 24.02.2021 um 16:52 Uhr)
https://www.aerzteblatt.de/nachrichten/121442/Rezeptormangel-auf-Immunzellen-koennte-mit-schwerem-COVID-19-Verlauf-verbunden-sein
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia (Hinzugefügt: 17.02.2021 um 14:46 Uhr)
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00968-1
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer (Hinzugefügt: 17.02.2021 um 14:38 Uhr)
https://www.researchsquare.com/article/rs-162289/v1
SARS-CoV-2: Bei abwehrgeschwächten Patienten verändert sich das Virus schneller (Hinzugefügt: 09.02.2021 um 10:03 Uhr)
https://www.aerzteblatt.de/nachrichten/120965/SARS-CoV-2-Bei-abwehrgeschwaechten-Patienten-veraendert-sich-das-Virus-schneller
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses (Hinzugefügt: 06.02.2021 um 09:18 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00019-7
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State (Hinzugefügt: 04.02.2021 um 09:41 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775827
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study (Hinzugefügt: 01.02.2021 um 21:25 Uhr)
https://pubmed.ncbi.nlm.nih.gov/32945944/
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up (Hinzugefügt: 01.02.2021 um 21:24 Uhr)
https://link.springer.com/article/10.1007%2Fs00415-020-10310-x
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? (Hinzugefügt: 01.02.2021 um 21:17 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30270-8/fulltext
B cell memory: understanding COVID-19 (Hinzugefügt: 01.02.2021 um 08:28 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(21)00037-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761321000376%3Fshowall%3Dtrue
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this? (Hinzugefügt: 31.01.2021 um 10:31 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00008-4/fulltext
Lessons in antiviral immunity (Hinzugefügt: 29.01.2021 um 09:07 Uhr)
https://science.sciencemag.org/content/371/6528/464.full
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry (Hinzugefügt: 28.01.2021 um 18:51 Uhr)
https://ard.bmj.com/content/annrheumdis/early/2021/01/26/annrheumdis-2020-219498.full.pdf
Disease modifying therapies and Covid-19 severity in Multiple Sclerosis (Hinzugefügt: 28.01.2021 um 18:25 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.26028
Immune response to SARS-CoV-2 in the nasal mucosa in children and adults (Hinzugefügt: 28.01.2021 um 13:53 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.26.21250269v1
Immunsuppression Rituximab (Hinzugefügt: 27.01.2021 um 18:01 Uhr)
https://www.ndr.de/nachrichten/info/73-Coronavirus-Update-Dem-Virus-zuvorkommen,podcastcoronavirus282.html#Immunsupprimierte
Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients (Hinzugefügt: 27.01.2021 um 09:37 Uhr)
https://pubmed.ncbi.nlm.nih.gov/32343415/
The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient - a case study (Hinzugefügt: 27.01.2021 um 09:37 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.23.21249554v1
Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future (Hinzugefügt: 23.01.2021 um 09:12 Uhr)
https://www.sciencemag.org/news/2021/01/monoclonal-antibodies-can-prevent-covid-19-successful-vaccines-complicate-their-future
Memory B Cells, Infection, and Vaccination (Hinzugefügt: 22.01.2021 um 08:58 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/01/19/memory-b-cells-infection-and-vaccination
Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells (Hinzugefügt: 22.01.2021 um 08:56 Uhr)
https://immunology.sciencemag.org/content/6/55/eabe4782.full
Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients (Hinzugefügt: 22.01.2021 um 08:53 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00041-3
SARS-CoV-2: Frühe Immunreaktion bestimmt den Verlauf von COVID-19 (Hinzugefügt: 20.01.2021 um 08:26 Uhr)
https://www.aerzteblatt.de/nachrichten/120307/SARS-CoV-2-Fruehe-Immunreaktion-bestimmt-den-Verlauf-von-COVID-19
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study (Hinzugefügt: 20.01.2021 um 08:24 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30429-4/fulltext
Divergent effects of acute versus chronic glucocorticoids in COVID-19 (Hinzugefügt: 19.01.2021 um 07:10 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00005-9/fulltext
Systemische Immunsuppression in Zeiten von COVID‐19: Müssen wir umdenken? (Hinzugefügt: 17.01.2021 um 20:02 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460968/
Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host (Hinzugefügt: 17.01.2021 um 07:43 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.10.20248871v1
Early immune pathology and persistent dysregulation characterise severe COVID-19 (Hinzugefügt: 16.01.2021 um 08:54 Uhr)
https://www.medrxiv.org/content/10.1101/2021.01.11.20248765v1
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study (Hinzugefügt: 14.01.2021 um 05:04 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00007-2/fulltext
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer (Hinzugefügt: 13.01.2021 um 19:40 Uhr)
https://www.nejm.org/doi/10.1056/NEJMc2031670
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiat (Hinzugefügt: 12.01.2021 um 08:07 Uhr)
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30392-7/fulltext
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation (Hinzugefügt: 11.01.2021 um 19:24 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v3
313 COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality (Hinzugefügt: 29.12.2020 um 09:31 Uhr)
https://ash.confex.com/ash/2020/webprogram/Paper138611.html
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study (Hinzugefügt: 26.12.2020 um 10:02 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30422-7/fulltext
U.K. variant puts spotlight on immunocompromised patients’ role in the COVID-19 pandemic (Hinzugefügt: 25.12.2020 um 08:11 Uhr)
https://www.sciencemag.org/news/2020/12/uk-variant-puts-spotlight-immunocompromised-patients-role-covid-19-pandemic
Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab (Hinzugefügt: 20.12.2020 um 09:55 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493633/
Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70 (Hinzugefügt: 18.12.2020 um 10:41 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.14.422555v2.full.pdf+html
Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion (Hinzugefügt: 18.12.2020 um 10:35 Uhr)
https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report (Hinzugefügt: 15.12.2020 um 09:44 Uhr)
https://www.nature.com/articles/s41467-020-19761-2
COVID-19: Wie Remdesivir die Infektion bei einem Patienten mit angeborener Immunschwäche beendete (Hinzugefügt: 15.12.2020 um 09:44 Uhr)
https://www.aerzteblatt.de/nachrichten/119359/COVID-19-Wie-Remdesivir-die-Infektion-bei-einem-Patienten-mit-angeborener-Immunschwaeche-beendete
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform (Hinzugefügt: 13.12.2020 um 10:46 Uhr)
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30305-2/fulltext
Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroqu (Hinzugefügt: 28.11.2020 um 12:52 Uhr)
https://ard.bmj.com/content/early/2020/11/24/annrheumdis-2020-218795
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic (Hinzugefügt: 27.11.2020 um 22:09 Uhr)
https://www.jns-journal.com/article/S0022-510X(20)30139-8/fulltext
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up (Hinzugefügt: 27.11.2020 um 22:07 Uhr)
https://link.springer.com/article/10.1007/s00415-020-10310-x
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies (Hinzugefügt: 27.11.2020 um 11:17 Uhr)
https://ard.bmj.com/content/79/5/667
Antikörper gegen CD 20: ein Risiko in der Pandemie? (Hinzugefügt: 23.11.2020 um 16:16 Uhr)
https://link.springer.com/article/10.1007/s15005-020-1512-1
Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome (Hinzugefügt: 23.11.2020 um 16:10 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665250/
Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab (Hinzugefügt: 16.11.2020 um 12:49 Uhr)
https://www.sciencedirect.com/science/article/pii/S004901722030192X?via%3Dihub
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease (Hinzugefügt: 16.11.2020 um 12:45 Uhr)
https://link.springer.com/article/10.1007%2Fs00296-020-04715-0
Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders (Hinzugefügt: 16.11.2020 um 12:43 Uhr)
https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14612
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases (Hinzugefügt: 16.11.2020 um 12:38 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/
Systemische Immunsuppression in Zeiten von COVID‐19: Müssen wir umdenken? (Hinzugefügt: 12.11.2020 um 20:28 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460968/
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host (Hinzugefügt: 12.11.2020 um 17:55 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2031364
Lymphopenie (Hinzugefügt: 04.11.2020 um 19:16 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.04.236521v1
Compromised humoral functional evolution tracks with SARS-CoV-2 mortality (Hinzugefügt: 03.11.2020 um 20:08 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(20)31459-8
A dynamic COVID-19 immune signature includes associations with poor prognosis (Hinzugefügt: 03.11.2020 um 19:44 Uhr)
https://www.nature.com/articles/s41591-020-1038-6
B cells and T cells mediate immunity to COVID-19 (Hinzugefügt: 03.11.2020 um 15:20 Uhr)
https://www.nature.com/articles/s41577-020-00436-4
Age-specific mortality and immunity patterns (Hinzugefügt: 02.11.2020 um 18:38 Uhr)
https://www.nature.com/articles/s41586-020-2918-0
Organtransplantation (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://link.springer.com/article/10.1007/s40472-020-00307-w
BZell Mangel (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008423/463806/Convalescent-plasma-therapy-for-B-cell-depleted
immunocompomises patient (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.09.20.20196899v1
Lymphozytopenie (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.medrxiv.org/content/10.1101/2020.10.02.20200931v1
Immunsystem (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.sciencedirect.com/science/article/pii/S0042682220301720
"Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen" (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.awmf.org/leitlinien/detail/ll/018-037.html
Bzell Mangel (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ashpublications.org/blood/article/doi/10.1182/blood.2020008423/463806/Convalescent-plasma-therapy-for-B-cell-depleted
Interferon (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2020/09/28/interferon-and-the-coronavirus
Prolonged SARS-CoV-2 replication (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa666/5934826
Antibodies IFN (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://science.sciencemag.org/content/370/6515/eabd4585.full
TZellen (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41590-020-0798-y
TZellen (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/nachrichten/116178/T-Helferzellen-bei-COVID-19-Risikopatienten-ausgebremst
Lymphozyten (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.cell.com/immunity/fulltext/S1074-7613(20)30333-2
Lymphopenia (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.biorxiv.org/content/10.1101/2020.08.04.236521v1
Rituximab (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30270-8/fulltext
Leukozyten (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.frontiersin.org/articles/10.3389/fpubh.2020.00299/full
false negatives (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.nature.com/articles/s41409-020-0972-8
Rituximab (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://ard.bmj.com/content/early/2020/06/05/annrheumdis-2020-217955
Rolle des Immunsystems (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.aerzteblatt.de/archiv/216372/Infektion-mit-SARS-CoV-2-Abwehr-im-Ausnahmezustand
TZellen (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(20)31235-6
TZellen (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://immunology.sciencemag.org/content/5/49/eabd6160.full
SARS-CoV-2 in rituximab-treated (Hinzugefügt: 01.11.2020 um 15:56 Uhr)
https://link.springer.com/article/10.1007/s00415-020-10046-8

Mehr zum Thema "12 Risikogruppen?/ risk groups"

Schwangerschaft/ pregnancy 25. Oktober 2020 23:43 sonstige Vorerkrankungen/ other pre-existing illnesses 29. Oktober 2020 16:43 Interferon Antikörper/ interferon antibodies 25. Oktober 2020 23:47 Krebs/ cancer 27. Oktober 2020 13:18 Rituximab 6. April 2021 09:16 sonst. Neurologie/ neurology 28. Oktober 2020 08:35 Trisomie 21/ trisomy 21 28. Oktober 2020 06:43 Gene, Blutgruppe/ genes, blood type 25. Oktober 2020 23:47 Nierenerkrankung/ kidney disease 27. Oktober 2020 21:00 Auto- Antikörper allg./ auto antibodies 9. November 2020 07:55 Gewicht/ weight 27. Oktober 2020 20:59 Diabetes 27. Oktober 2020 21:01 MS 13. Januar 2021 21:05 kardiovaskuläre Erkrankungen/ cardiovascular diseases 25. Oktober 2020 23:53 Lungenerkrankungen/ lung disease 27. Oktober 2020 21:03 Immunsuppression/Immundefizienz 25. Oktober 2020 23:45 Alter/ age 25. Oktober 2020 23:41 Prognosen/ prognoses 26. Oktober 2020 00:45 allgemeines/ general 27. Oktober 2020 20:54

Weitere Themen

0 Corona- Pandemie 1 Virus SARS-Cov-2 2a Übertragungswege/ transmission routes 2b Übertragungssituationen?/ transmission situations 2c Reisen/ travelling 3 NPIs 4 Masken/ masks 5 Luftreiniger/air cleaner 6 persönliche Risikoreduktion/ risc reduction 7a allg. zu Impfungen/ vaccinations 7b In D aktuell verfügbare Impfstoffe gegen Originalvirus 7c in D verfügbare angepasste Impfstoffe gegen Omicron BA.1 7d aktuell verfügbare Impfstoffe gg BA.2 7y Immunität nach Infektion/ immunity after infection 7e in D aktuell verfügbare Impfstoffe gegen BA.4/5 7f XBB- Booster 8 PrEP 9 Tests/ testing 10 Was tun wenn infiziert?/ To do when tested positive? 11 Erkrankung Symptome Covid-19/ disease symptoms 12 Risikogruppen?/ risk groups 13 Frühtherapie/ early treatment 14a Behandlung allg./ treatment 14b monoklonale Antikörper 14y evtl. wirksame Behandlung 14z nicht empfohlene Behandlung 15 Long- Covid/ Post- Covid 16 Rechtliches/ legal information 17 Meine persönliche Vorgehensweise/ My personal approach 18 NICHT SARS-CoV-2

« Zurück zur Übersicht